| scholarly article | Q13442814 |
| P50 | author | Shyam Sundar | Q58941021 |
| Poonam Salotra | Q28869475 | ||
| P2093 | author name string | Jean-Claude Dujardin | |
| Suman Rijal | |||
| Louis Maes | |||
| Paul Cos | |||
| Vasundhra Bhandari | |||
| Kristel Kuypers | |||
| Sarah Hendrickx | |||
| Julien Lonchamp | |||
| Craig D Shaw | |||
| Katharine Carter | |||
| Raquel Andrea Inocêncio da Luz | |||
| P2860 | cites work | In vivo interference of paromomycin with mitochondrial activity of Leishmania. | Q50529065 |
| Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. | Q51765295 | ||
| A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. | Q53900097 | ||
| Analysis of stage-specific expression of basic proteins in Leishmania infantum | Q62579648 | ||
| Kala-azar elimination programme in India | Q64132519 | ||
| Development and characterization of paromomycin-resistant Leishmania donovani promastigotes | Q77352855 | ||
| Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in Leishmania mexicana | Q82344940 | ||
| Paromomycin in the treatment of leishmaniasis | Q94699168 | ||
| Metabolomics to unveil and understand phenotypic diversity between pathogen populations | Q28476399 | ||
| Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing | Q28480626 | ||
| Drug resistance in leishmaniasis | Q29616242 | ||
| Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan | Q33603346 | ||
| Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study | Q33737825 | ||
| Injectable paromomycin for Visceral leishmaniasis in India | Q34639916 | ||
| Paromomycin | Q34864208 | ||
| Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine | Q35005213 | ||
| In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species | Q35006918 | ||
| Visceral leishmaniasis - current therapeutic modalities. | Q36508340 | ||
| Drug unresponsiveness & combination therapy for kala-azar | Q36508353 | ||
| Combination therapy for visceral leishmaniasis | Q37698756 | ||
| Biofilms: an extra hurdle for effective antimicrobial therapy | Q37740154 | ||
| In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences | Q41844113 | ||
| Paromomycin: uptake and resistance in Leishmania donovani. | Q41855565 | ||
| In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells | Q41901399 | ||
| Treatment of Visceral Leishmaniasis in 2010: Direction From Bihar State, India | Q42879827 | ||
| Stage specific developmental changes in the mitochondrial and surface membrane associated redox systems of Leishmania donovani promastigote and amastigote | Q42975045 | ||
| Profiling of lipids in Leishmania donovani using hydrophilic interaction chromatography in combination with Fourier transform mass spectrometry | Q43019143 | ||
| Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. | Q43953352 | ||
| Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase B and surface metalloprotease glycoprotein 63 in the Leishmania donovani complex | Q44785806 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antimony | Q1099 |
| paromomycin | Q415625 | ||
| infectious disease | Q18123741 | ||
| P304 | page(s) | e1664 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | PLoS Neglected Tropical Diseases | Q3359737 |
| P1476 | title | Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol | |
| P478 | volume | 6 |
| Q38088424 | (Post-) Genomic approaches to tackle drug resistance in Leishmania. |
| Q28082097 | Advances in Development of New Treatment for Leishmaniasis |
| Q92500125 | Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei |
| Q33728704 | Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum |
| Q28550306 | Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain |
| Q34328882 | Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects |
| Q37712969 | Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani |
| Q39014583 | Evaluating drug resistance in visceral leishmaniasis: the challenges |
| Q53120855 | Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum. |
| Q37664065 | Evolution of resistance to single and combined floral phytochemicals by a bumble bee parasite. |
| Q38904942 | Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations. |
| Q46921246 | Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum |
| Q28546940 | Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major |
| Q37023262 | Genomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovani |
| Q36001763 | Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes |
| Q35859984 | In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model |
| Q46481419 | In vitro 'time-to-kill' assay to assess the cidal activity dynamics of current reference drugs against Leishmania donovani and Leishmania infantum |
| Q28540828 | In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis |
| Q53541333 | Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum. |
| Q39063747 | Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome |
| Q28484463 | Leishmania donovani develops resistance to drug combinations |
| Q44872017 | Leishmania epidemiology, diagnosis, chemotherapy and vaccination approaches in the international network of Pasteur Institutes |
| Q38904947 | Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure |
| Q40078925 | Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility |
| Q42379574 | Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani |
Search more.